THE DETECTION RATE AND VARIANTS OF MONOCLONAL GAMMOPATHY AMONG PATIENTS IN A MULTIDISCIPLINARY THERAPEUTIC HOSPITAL

DOI: https://doi.org/10.29296/25877305-2019-02-11
Download full text PDF
Issue: 
2
Year: 
2019

N. Mrykhin(1); Professor L. Lysenko(1), MD; N. Chebotareva(1), Candidate of Medical Sciences; V. Rameev(1), Candidate of Medical Sciences; T. Androsova(1), Candidate of Medical Sciences; S. Roshchupkina(1); E. Gitel(1), Candidate of Medical Sciences; I. Kogarko(3), MD; S. Maryina(2) 1-I.M. Sechenov First Moscow State Medical University (Sechenov University) 2-National Medical Research Center of Hematology, Moscow 3-Semenov Institute of Chemical Physics Russian Academy of Sciences

Oligosecretory monoclonal gammopathy is the result of the hyperproduction of a small proliferating cell clone, which, after various periods, can transform into overt secreting hematological tumors, but may be a cause of non-tumor organ and tissue damage, including kidney disease. The frequency, severity, and spectrum of monoclonal gammopathy in patients from different departments of a multidisciplinary therapeutic hospital have been studied. The nosological characteristics of diseases associated with monoclonal gamma of undetermined significance (MGUS) are given; special attention is paid to kidney diseases, including immune-mediated diseases, the association of which to MGUS has been least studied.
Keywords: 
monoclonal gammopathy
monoclonal gammopathy of indeterminate significance
protein electrophoresis
protein electrophoresis and immunofixation
free light chains
Freelite method
multiple myeloma
AL amyloidosis
light-chain deposition disease
chronic glomerulonephritis
HCV-related cryoglobulinemic glomerulonephritis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma // Curr. Hematol. Malig. Rep. – 2010; 5 (2): 62–9. DOI: 10.1007/s11899-010-0047-9.
  2. Zingone A., Kuehl M. Pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma // Semin Hematol. – 2011; 48 (1): 4–12. DOI: 10.1053/j.seminhematol.2010.11.003.
  3. Merlini G., Palladini G. Differential diagnosis of monoclonal gam-mopathy of undetermined significance // Hematology. Am. Soc. Hematol. Educ. Program. – 2012; 2012: 595–603. DOI: 10.1182/asheduca-tion-2012.1.595.
  4. Knight G., Gao L., Gragnani L. et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryo-globulinemic vasculitis and B cell malignancies // Arthr. Rheum. – 2010; 62: 2152–9. DOI: 10.1002/art.27490.
  5. Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management // Am. J. Hematol. – 2011; 86: 181–6. DOI: 10.1002/ajh.21934.
  6. Debiec H., Hanoy M., Francois A. et al. Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor // J. Am. Soc. Nephrol. – 2012; 23 (12): 1949–54. DOI: 10.1681/ASN.2012060577.
  7. Kapoulas S., Raptis V., Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies // Nephrol. Ther. – 2015; 11 (3): 135–43. DOI: 10.1016/j.nephro.2014.12.005.
  8. Bridoux F., Leung N., Hutchison C. et al. Diagnosis of monoclonal gammopathy of renal significance // Kidney Int. – 2015; 87 (4): 698–711. DOI: 10.1038/ki.2014.408.
  9. Kyle R., Therneau T., Rajkumar S. et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later // Mayo Clin. Proc. – 2004; 79 (7): 859–66. DOI: 10.1016/S0025-6196(11)62151-4.
  10. Landgren O., Kyle R., Pfeiffer R. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study // Blood. – 2009; 113: 5412–7. DOI: 10.1182/blood-2008-12-194241.
  11. Landgren O., Graubard B., Katzmann J. et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey // Leukemia. – 2014; 28 (7): 1537–42. DOI: 10.1038/leu.2014.34.
  12. Kyle R., Rajkumar S. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression // Br. J. Haematol. – 2007; 139 (5): 730–43. DOI: 10.1111/j.1365-2141.2007.06873.x.
  13. Landgren O., Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes // J. Intern. Med. – 2017; 281 (4): 365–82. DOI: 10.1111/joim.12590.
  14. Doyle L., Gundrum J., Farnen J. et al. Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS) // Blood. – 2009; 114 (22): 4883.
  15. Weiss B., Abadie J., Verma P. et al. A monoclonal gammopathy precedes multiple myeloma in most patients // Blood. – 2009; 113: 5418–22. DOI: 10.1182/blood-2008-12-195008.
  16. Kyle R. Monoclonal gammopathy of undetermined significance: natural history in 241 cases // Am. J. Med. – 1978; 64: 814–26.
  17. Go R., Rajkumar S. How I manage monoclonal gammopathy of undetermined significance // Blood. – 2018; 131 (2): 163–73. DOI: 10.1182/blood-2017-09-807560.
  18. Rajkumar S., Kyle R., Therneau T. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance // Blood. – 2005; 106: 812–7. DOI: 10.1182/blood-2005-03-1038.
  19. Bida J., Kyle R., Therneau T. et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients // Mayo Clin. Proc. – 2009; 84 (8): 685–93. DOI: 10.1016/S0025-6196(11)60518-1.
  20. Leung N., Bridoux F., Hutchison C. et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant // Blood. – 2012; 120 (22): 4292–5. DOI: 10.1182/ blood-2012-07-445304.
  21. Sethi S., Fervenza F., Rajkumar S. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions // Curr. Opin. Nephrol. Hypertens. – 2016; 25: 127–37. DOI: 10.1097/MNH.0000000000000201.
  22. Steiner N., Göbel G., Suchecki P. et al. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients // Oncotarget. – 2017; 9 (2): 2344–56. DOI:10.18632/oncotarget.23412.